1.
Cell Stem Cell
; 9(5): 397-401, 2011 Nov 04.
Article
in English
| MEDLINE
| ID: mdl-22056137
ABSTRACT
Stock market volatility in the cell therapy industry has greatly hindered the investment necessary to fund translational therapies. Here, we review the volatility of leading companies and suggest that a distinct industry is maturing to a point at which the volatility should subside, providing a more attractive environment for future growth.